This gene-based therapeutics stock could nearly triple, analysts say
Three firms initiated coverage of the the gene-based therapeutics company.
We haven't written up this one. CNBC World has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.